Kyle Jenne - 26 Feb 2024 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role: EVP, Chf GL Pdt Str Ofcr
Signature: By: Patrick R. O'Neil, attorney-in-fact For: Kyle Jenne
Issuer symbol: IONS
Transactions as of: 26 Feb 2024
Net transactions value: $0
Form type: 4
Filing time: 13 Mar 2024, 17:52:16 UTC
Next filing: 06 Jan 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IONS	Non-Qualified Stock Option (right to buy)	Award	$0	+65,203		$0.000000	65,203	26 Feb 2024	Common Stock	65,203	$46.10	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant on 02/26/2024 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2020 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 02/26/2024. 25% of the shares subject to the option will vest and become exercisable on 02/26/2025. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

Content

Grant on 02/26/2024 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2020 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 02/26/2024. 25% of the shares subject to the option will vest and become exercisable on 02/26/2025. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.